Press Releases & Announcements

ACTG ANNOUNCES INITIATION OF A5355, CLINICAL TRIAL STUDYING NEW CMV VACCINE

Dec 16, 2021

SCOTT HAMMER

Dec 07, 2021

POORER MUSCLE QUALITY AND QUANTITY WITH ART INITIATION IS ASSOCIATED WITH GREATER INFLAMMATION AND IMMUNE ACTIVATION

Dec 01, 2021

ACTG ANNOUNCES INITIATION OF CLO-FAST, ITS FIRST TRIAL EVALUATING A THREE-MONTH TB TREATMENT

Nov 10, 2021

ACTG LAUNCHES STUDY EVALUATING HOW A HISTORY OF COVID-19 AND PRIOR INVESTIGATIONAL COVID-19 TREATMENT MAY AFFECT COVID-19 VACCINE RESPONSE

Nov 03, 2021

ACTG ANNOUNCES GRADUATION OF INVESTIGATIONAL INHALED COVID-19 TREATMENT TO PHASE 3 STUDY IN ACTIV-2

Oct 21, 2021

A5360 (MINMON): A SINGLE-ARM STUDY TO EVALUATE THE FEASIBILITY AND EFFICACY OF A MINIMAL MONITORING STRATEGY TO DELIVER PAN-GENOTYPIC RIBAVIRIN-FREE HCV THERAPY TO POPULATIONS LIVING WITH HCV WHO ARE HCV TREATMENT NAÏVE WITH EVIDENCE OF ACTIVE HCV INFECTION

Oct 20, 2021

A5349: RIFAPENTINE-CONTAINING TREATMENT SHORTENING REGIMENS FOR PULMONARY TUBERCULOSIS

Oct 20, 2021

A5349: RIFAPENTINE-CONTAINING TREATMENT SHORTENING REGIMENS FOR PULMONARY TUBERCULOSIS

Oct 20, 2021

ACTG TO PRESENT DATA ON INVESTIGATIONAL NEW COVID-19 TREATMENT AT IDWEEK 2021

Sep 29, 2021

ACTG ANNOUNCES GRADUATION OF NOVEL POLYCLONAL ANTIBODY THERAPY SAB-185 TO PHASE 3 STUDY IN ACTIV-2

Sep 27, 2021

ACTG ANNOUNCES DATA FROM ACTIV-2 STUDY, DEMONSTRATING BENEFIT OF BRII-196 AND BRII-198 IN NON-HOSPITALIZED PARTICIPANTS WITH COVID-19

Aug 26, 2021